Document is current
Any future updates will be listed below
-
Authors
Joensuu, Heikki https://orcid.org/0000-0003-0281-2507
Reichardt, Annette
Eriksson, Mikael
Hohenberger, Peter https://orcid.org/0000-0001-5359-5923
Boye, Kjetil https://orcid.org/0000-0002-5552-6283
Cameron, Silke https://orcid.org/0000-0003-2761-0960
Lindner, Lars H.
Jost, Philipp J. https://orcid.org/0000-0003-2454-0362
Bauer, Sebastian https://orcid.org/0000-0001-5949-8120
Schütte, Jochen
Lindskog, Stefan
Kallio, Raija
Jaakkola, Panu M.
Goplen, Dorota
Wardelmann, Eva https://orcid.org/0000-0001-6788-4910
Reichardt, Peter
-
Funding
Funding for this research was provided by:
Novartis (None, None)
Sigrid Juselius Foundation, Finland; www.sigridjuselius.fi Louise and Henrik Kuningas Foundation, Finland; www.lhkstiftelse.fi
- License Information
-
More Information
Article History
Received: 21 February 2024
Revised: 18 May 2024
Accepted: 28 May 2024
First Online: 11 June 2024
Competing interests
: HJ has a consulting/advisory role in Orion Pharma, Neutron Therapeutics, and Maud Kuistila Foundation, has received research grants from Mersana Therapeutics and Defence Therapeutics, and has stock ownership in Orion Pharma and Sartar Therapeutics. ME has received consulting fees from Blueprint Medicines and institutional research funding from Novartis. PH has received honoraria and research support from Novartis. KB has had a consulting or advisory roles for Bayer, GSK, Incyte, Deciphera, and NEC Oncoimmunity; invited speaker roles for Lilly, Novartis, and Deciphera Pharmaceuticals, LLC; and institutional research funding from Lilly and Merck. PJJ has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS and Celgene, Pierre Fabre, Janssen/Johnson&Johnson, MSD, Merck, and AstraZeneca. SB has received institutional research funding from Blueprint Medicines, Incyte, and Novartis, honoraria from PharmaMar, Eli Lilly & Co, and Novartis, has an advisory role in Adcendo, Bayer, Blueprint Medicines, Böhringer Ingelheim, Daiichi Sankyo, Deciphera, Eli Lilly & Co, GSK, Exelixis, Nanobiotix, Novartis, and Roche, and has received travel support from PharmaMar. PMJ has received honoraria from Ipsen, MSD, and Orion Pharma. EW has received honoraria from Bayer, Novartis, Roche, Bristol Myers Squibb, and Boehringer Ingelheim. PR has received honoraria for participation in Advisory Boards for Bayer, Novartis, Roche, Deciphera, Mundibiopharma, PharmaMar, Blueprint Medicines, GSK, Boehringer Ingelheim and for lectures for Deciphera, PharmaMar, and Boehringer Ingelheim. The remaining authors declare no potential conflicts.
: An institutional review committee of the study site and/or the country approved the study protocol as per the local legislation (Helsinki University Hospital Operative Ethics Committee, HUS/508/E6/03; Landesamt für Gesundheit und Soziales Ethik-Kommission des Landes Berlin; Regional Committee for Medical Research Ethics South East Norway; Regionala Etikprövningsnämnden Lund). The patients provided written informed consent before study entry and before any study related procedures were carried out. The trial was conducted following the Good Clinical Practice principles and the Declaration of Helsinki guidelines.
